Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Literature Review: The Dual Role of Domperidone in Gastroparesis and Lactation

Author(s):  Phan Ha, DeReese Annie, Day A J, Carvalho Maria

Issue:  May/Jun 2014 - Volume 18, Number 3
View All Articles in Issue

Page(s):  203-207

Literature Review: The Dual Role of Domperidone in Gastroparesis and Lactation Page 1
Literature Review: The Dual Role of Domperidone in Gastroparesis and Lactation Page 2
Literature Review: The Dual Role of Domperidone in Gastroparesis and Lactation Page 3
Literature Review: The Dual Role of Domperidone in Gastroparesis and Lactation Page 4
Literature Review: The Dual Role of Domperidone in Gastroparesis and Lactation Page 5

Download in electronic PDF format for $75

Abstract:  Domperidone is a prokinetic agent used as a second-line treatment option for gastroparesis in those unable to tolerate metoclopramide. Via inhibition of dopamine- 2 receptors within the gastrointestinal tract and various parts of the central and peripheral nervous system, domperidone helps to facilitate peristalsis and gastric emptying. A major side effect of domperidone is prolactinemia, allowing it to be used off-label for the purpose of inducing lactation. In the U.S., domperidone is currently not U.S. Food and Drug Administration approved due to various case reports and literature associating the risks of sudden cardiac death and ventricular arrhythmia with the use of domperidone. Despite the evidence against the use of domperidone, it is still being widely used in Canada and Europe for both gastroparesis and to induce milk let-down. This article is a literature review intending to assess the risks associated with the use of domperidone in gastroparesis and lactation.

Related Keywords: Ha Phan, domperidone, prokinetic agent, dopamine 2 receptors, prolactinemia, lactation induction, U.S. Food and Drug Administration, FDA, sudden cardiac death, arrhythmia, gastrointestinal motility, prolonged QTc interval, breast milk

Related Categories: GASTROENTEROLOGY, ADVERSE DRUG EVENTS, CARDIOLOGY, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE, LITERATURE REVIEW

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Literature Review: The Dual Role of Domperidone in Gastroparesis and Lactation
Phan Ha
, DeReese Annie, Day A J, Carvalho Maria
May/Jun 2014
Pg. 203-207

Domperidone in Lactation: Use as a Galactagogue
Albright Lisa M
Sep/Oct 2004
Pg. 329-335

Use of Domperidone as a Prokinetic and Antiemetic
Albright Lisa M
Mar/Apr 2005
Pg. 120-125

View Sample
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
Jul/Aug 2016
Pg. 351

View Sample
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
Sep/Oct 2017
Pg. 356

Domperidone 5 mg/mL in Oral Mix
Allen Loyd V Jr
Jul/Aug 2019
Pg. 316

U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Miller David G
Jul/Aug 2015
Pg. 303-305

U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line
Snow Stephen T
, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Jan/Feb 2019
Pg. 32-33

U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Allen Loyd V Jr
Nov/Dec 2015
Pg. 487-488

Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Brunner Scott
Jul/Aug 2020
Pg. 296-297

U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Yoch Doug
Mar/Apr 2017
Pg. 95-102

The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter
Miller David G
May/Jun 2014
Pg. 208

Wetting and/or Solubilizing Agents, Featured Excipient:
Allen Loyd V Jr
Jul/Aug 2001
Pg. 310-312

Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration
Kupiec Tom
, Kemp Jesse
Jul/Aug 2007
Pg. 326-327

Domperidone 5 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
Nov/Dec 2021
Pg. 500

The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone
Brunner Scott
Jan/Feb 2023
Pg. 22-23

U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)
Nov/Dec 2016
Pg. 457-458

Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Allen Loyd V Jr
Sep/Oct 2015
Pg. 389-390

U.S. Food and Drug Administration Requests for Input on HR 3204 Enactment: The Drug Quality and Security Act of 2013
Miller David G
Jan/Feb 2014
Pg. 35-36

Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients
Allen Loyd V Jr
Nov/Dec 2023
Pg. 474-481

Return to Top